Taken together, our studies reinforce the notion that hepatic PDE4D mediates liver-kidney crosstalk in NAFLD-associated CKD via TGF-β1-SMAD signaling and thus provide a novel therapeutic strategy for CKD. Here, TGFB1 is linked to metabolic dysfunction-associated steatotic liver disease.